BidaskClub upgraded shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a hold rating to a buy rating in a report published on Wednesday.

Other equities research analysts have also recently issued research reports about the stock. Cantor Fitzgerald set a $18.00 target price on shares of Aurinia Pharmaceuticals and gave the company a buy rating in a research note on Monday, October 1st. HC Wainwright reiterated a buy rating and issued a $15.00 target price on shares of Aurinia Pharmaceuticals in a research note on Wednesday, September 26th. ValuEngine upgraded shares of Aurinia Pharmaceuticals from a hold rating to a buy rating in a research note on Tuesday, August 28th. Finally, Zacks Investment Research upgraded shares of Aurinia Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, November 20th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of Buy and a consensus target price of $11.95.

Shares of NASDAQ:AUPH opened at $6.15 on Wednesday. Aurinia Pharmaceuticals has a 52-week low of $4.41 and a 52-week high of $6.69. The stock has a market capitalization of $524.86 million, a PE ratio of -6.68 and a beta of 2.23.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its earnings results on Thursday, November 8th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.04). Aurinia Pharmaceuticals had a negative net margin of 7,280.85% and a negative return on equity of 36.10%. The company had revenue of $0.38 million during the quarter, compared to the consensus estimate of $0.07 million. Sell-side analysts predict that Aurinia Pharmaceuticals will post -0.73 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AUPH. Franklin Resources Inc. lifted its stake in shares of Aurinia Pharmaceuticals by 6.1% in the third quarter. Franklin Resources Inc. now owns 1,838,500 shares of the biotechnology company’s stock valued at $12,208,000 after buying an additional 105,300 shares during the period. FMR LLC lifted its stake in shares of Aurinia Pharmaceuticals by 2.1% in the third quarter. FMR LLC now owns 4,680,959 shares of the biotechnology company’s stock valued at $31,082,000 after buying an additional 95,650 shares during the period. Stanley Laman Group Ltd. bought a new stake in shares of Aurinia Pharmaceuticals in the second quarter valued at about $276,000. Ironwood Investment Management LLC lifted its stake in Aurinia Pharmaceuticals by 18.0% during the second quarter. Ironwood Investment Management LLC now owns 218,568 shares of the biotechnology company’s stock worth $1,231,000 after purchasing an additional 33,279 shares during the period. Finally, Jane Street Group LLC bought a new position in Aurinia Pharmaceuticals during the third quarter worth about $182,000. Institutional investors and hedge funds own 25.18% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

See Also: How interest rates affect municipal bond prices

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.